Diary - News
All news iDD biotech is granted new Patents in the USA and in China about its Fc optimized MAbs anti-CD19
Two important MAbs of iDD biotech have been granted new Patents abroad: in the USA for iDD002 (US Patent No. 9,120,856) and in China for iDD001 (WO 2012/010562).
These two new patents will support the development of therapeutic MAb anti-CD19, with high killing activity against many CD19 positive B cell malignancies.
From its proprietary MAb libraryand by using its MAb design advanced platform (WO2012/010602), iDD biotech has generated next generation, pro-apoptotic humanized, Fc optimized and afucosylated MAbs to enhance antibody dependent cellular cytotoxicity (ADCC), with or without complement dependent cytotoxicity (CDC) activities, respectively IDD001 and IDD002. Their potent in vitro and in vivo activity against B-LAL have been demonstrated.
Read the press release
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree